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Background: No studies have examined risk factors for the transition from pre-diabetes to 
diabetes in populations with widespread obesity and diabetes. We determined proximal changes 
and factors affecting the transition among Mexican-Americans with pre-diabetes.
Methods: Participants with pre-diabetes (n=285) were recruited from our randomly sampled 
population-based Cameron County Hispanic Cohort. These participants were followed for an 
average of 27 months with repeat examination every 3 to 4 months. Metabolic health was defined 
as having less than 2 metabolic abnormalities (e.g., hypertension, elevated low-density lipopro-
tein, etc). Diabetes was identified as fasting blood glucose ≥126 mg/dL, glycated hemoglobin 
≥6.5% and/or on hypoglycemic medication.
Results: Ninety-six of 285 (33.7%) participants transitioned to overt diabetes. The increased risk 
of diabetes in the metabolically unhealthy varying with follow-up time was 81% (adjusted odds 
ratio [OR]: 1.81; 95% CI: 1.09–3.02). The risk of diabetes increased 8% for each kg/m2 of increase 
in body mass index (BMI, OR: 1.08; 95% CI: 1.05–1.11) independent of covariates. Transition to 
diabetes was accompanied by a mean increase in BMI of 0.28 kg/m2, and deterioration in meta-
bolic health of 9% (OR: 1.09; 95% CI: 1.003–1.18) compared with those who did not transition.
Conclusions: Deteriorating metabolic health and/or increasing BMI significantly raises the 
risk of transitioning from pre-diabetes to diabetes. Transition itself was accompanied by further 
increase in BMI and deterioration in metabolic health. These data underline the importance of 
improving metabolic health and avoiding weight gain in pre-diabetes as simple but clear diabetes 
prevention targets, and emphasize the importance of lifestyle management.
Keywords: transition, pre-diabetes, diabetes, predictors, risk, Mexican-Americans, Hispanic, Latino
Introduction
The prevalence of type 2 diabetes has grown to epidemic proportions globally in 
the last few decades.1,2 The burden is expected to increase even further due to aging, 
urbanization and the increasing prevalence of physical inactivity and obesity.2 In the 
USA, nearly 24 million persons have diabetes. One-quarter are undiagnosed and are 
unaware of their condition. At least 57 million citizens have pre-diabetes, defined as 
impaired fasting glucose of 100–125 mg/dL.3 By 2050, rates of diagnosed diabetes 
are projected to reach 48 million.3 Globally, the International Diabetes Federation 
estimates that there are currently 415 million people with diabetes, half of whom are 
undiagnosed, and three-quarters live in low- and middle-income countries.4 Similarly, 
the US burden is greatest in minorities such as Mexican-Americans.3
Impaired fasting glucose (100–125 mg/dL), impaired glucose tolerance (140–199 
mg/dL at 2 hours) and/or impaired glycated hemoglobin (HbA
1c
, 5.7–6.4%) are 
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 classified as pre-diabetes.5,6 The oral glucose tolerance test is 
not widely used due to inconvenience, greater cost and lower 
reproducibility than fasting blood glucose (FBG) or HbA
1c
,6 
which are commonly used in clinics and in population-based 
studies assessing the risk of diabetes. Several longitudinal 
studies support the observation that pre-diabetes is a risk fac-
tor for diabetes, cardiovascular disease and even cancer,7–10 
but no studies have examined risk factors for the transition 
from pre-diabetes to diabetes and the proximal changes 
accompanying this transition in populations with widespread 
obesity and diabetes. The only relevant publication we are 
aware of is a longitudinal study among American-Indians 
without diabetes which showed that pre-diabetes at baseline 
was an independent predictor of transition to type 2 diabetes, 
compared to individuals with normal glucose metabolism 
at baseline.11 That study found that measures of baseline 
obesity, hemoglobin (HbA
1c
), FBG, 2-hour fasting plasma 
glucose, fasting insulin, albuminuria and insulin resistance 
helped predict transition.11 However, understanding proximal 
events by characterizing established metabolic and other 
markers accompanying transition to overt type 2 diabetes 
should yield better understanding of the precipitating risk 
factors among those with pre-diabetes.7–9 This would permit 
distinguishing the person with pre-diabetes at risk of transi-
tion from those who are not. This study was to determine the 
factors affecting transition from pre-diabetes to overt type 2 
diabetes and proximal changes accompanying that transition 
in a Mexican-American cohort with high prevalence rates 
of diabetes (28%), obesity and undiagnosed pre-diabetes 
(31.6%).12 Unique aspects of this intensive study are that 
it provides longitudinal data, has general application and 
particular relevance for the largest and most rapidly growing 
minority in the USA.
Methods
Study participants
We created a nested cohort selected from our larger com-
munity-recruited and randomly sampled Cameron County 
Hispanic Cohort (CCHC, n=3,627 at the time of this study; 
currently 4,300), an on-going homogenous Mexican- American 
cohort.13,14 From this cohort, we selected 285 adult participants 
(Diabetes Risk Study [DRS] subjects) on the basis of pre-
diabetes (FBG ≥100 mg/dL and <126 mg/dL and/or HbA
1c
 
5.7%–6.4%) and examined them every 3 to 6 months for an 
average of 27 months (range: 3–129 months). The participants 
were randomly selected as part of the larger cohort, and we 
selected 285 out of about 900 randomly selected participants 
(28% already had diabetes and another 32% had pre-diabetes). 
So the 285 represented nearly all of those with pre-diabetes 
in the early days of the cohort. The DRS started from April, 
2004 and ended in December, 2015. This study was approved 
by the Committee for the Protection of Human Subjects of the 
University of Texas Health, Houston, TX, USA.
Admission DRS examinations
At enrollment to this nested cohort all DRS subjects provided 
written informed consent. They then responded to a detailed 
survey of sociodemographic characteristics, lifestyle includ-
ing physical activity, diet, medical and family history, and 
other potential exposures. Body measurements, including 
current weight, height, and waist and hip circumferences 
(HCs), were also taken.13,14 Weight was measured to the 
nearest tenth of a kilogram and height to the nearest tenth 
of a centimeter. Body mass index (BMI) was calculated by 
dividing weight in kilograms by height squared in meters (kg/
m2). Waist circumference (WC) was measured at the level 
of the umbilicus and HC at the level of maximum width of 
buttocks with participants standing erect. Three blood pres-
sure (BP) measurements were taken 5 minutes apart, and the 
average of the second and third reading was used.
In line with standard CCHC protocols, all DRS subjects 
provided blood sample at each visit following a 10 hours 
overnight fast. After collection, samples were placed on ice 
and centrifuged within 30 minutes. Following processing, 
samples were frozen at −80°C. Laboratory studies included 
complete blood count, metabolic and lipid panels, and HbA
1c
 
at a Clinical Laboratory Improvement Amendments certified 
laboratory. Fasting serum insulin was consistently performed 
in-house using Mercodia immunoassays (Uppsala, Sweden). 
Homeostasis model assessment insulin resistance (HOMA-
IR) index was calculated as (glucose [nmol/L]×insulin [µU/
mL]/22.5).15 High-sensitivity C-reactive protein (CRP) levels 
were measured using Quantikine® ELISA kit (R&D Systems, 
Inc., Minneapolis, MN, USA). The coefficient of variations 
for all biomarkers ranged from 0.99% to 11%.
Intermediate follow-up examinations 
(Short visit)
Every 3 to 4 months, a follow-up visit was performed, some 
of which were in the home. Questionnaires were administered 
to update demographic data, determine changes in diagnosed 
conditions, doctor visits or hospitalization since the last visit. 
Weight, WC, HC and BP were measured, and a blood sample 
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Transition from pre-diabetes to diabetes
Annual follow-up examinations  
(Long visit)
Once a year, a complete clinical examination identical to the 
admission protocol was performed in the clinic research unit. 
Physical activity and dietary questionnaire were re-admin-
istered. The International Physical Activity Questionnaire 
(IPAQ) short-form16 in the early years of the cohort or the 
Godin Leisure-Time Exercise Questionnaire instruments 17 in 
the later years of the cohort as reported previously18 was used 
to re-access physical activity in a typical week according to 
intensity, frequency (times/week) and duration (minutes/time). 
Metabolic equivalent (MET) adjusted minutes of moderate 
and vigorous physical activity in the last week were calculated 
based on responses.19 Moderate and vigorous physical activ-
ity ≥600 MET adjusted minutes was considered meeting US 
physical activity guidelines (USDHHS).19 Fruit and vegetable 
consumption was assessed by asking subjects how many por-
tions of fruit and vegetables they ate daily using the Food Fre-
quency Questionnaire.20 A portion size was defined as a half 
a cup of fresh, frozen or canned produce or a medium-sized 
piece of produce.21,22 Eating ≥5 fruit and vegetable portions 
daily was considered meeting US guidelines.21,22
Identification of diabetes
Diabetes was identified by the 2010 definition of diabetes of 
the American Diabetes Association: an FBG ≥126 mg/dL or 
HbA
1c
 >6.5%6 or the subjects’ reporting being told by a health 
care provider that they had diabetes or if they were taking 
hypoglycemic medication. Transition to diabetes required two 
fasting FBG measurements at least 1 day apart meeting the 
American Diabetes Association criteria for diabetes.
Definition of metabolic health
Metabolic health was defined as having less than 2 of the 
following metabolic abnormalities: systolic BP (SBP) 
≥130 mmHg and/or diastolic BP (DBP) ≥85 mmHg or on 
antihypertensive medication; triglyceride ≥150 mg/dL and 
high-density lipoprotein-cholesterol (HDLC) <40 mg/dL 
in men or <50 mg/dL in women.23,24 To avoid bias, we did 
not use blood glucose levels nor diabetes medication in the 
definition of metabolic health in our comparison of the risk 
for diabetes in metabolically healthy and unhealthy groups.
Statistical analysis
Descriptive analyses were conducted to compare the char-
acteristics of the DRS subjects who did or did not transition 
to diabetes. Log-transformation was conducted to normalize 
the distribution of continuous variables as appropriate. The 
2-sample t-test was used to compare means for continuous 
data. The Chi-square test was used to compare phenotypes 
for categorical data. Incidence density (person-years per 100 
individuals) was calculated to evaluate the transition rate 
from pre-diabetes to diabetes, further classified by metabolic 
health status at enrollment.
To explore the predictors reflecting the transition from 
pre-diabetes to diabetes, the first overt diabetes transition was 
treated as the outcome. Since the outcome measurements at 
enrollment and the follow-up every 3–6 months are expected 
to be correlated, Generalized Estimating Equations (GEE) 
models were used to analyze the association between predict-
ing factors and the risk of diabetes. Potential confounders 
were adjusted for likely associated with diabetes outcomes. 
Since our previous findings suggested the importance of 
metabolic health on diabetes risk25 and the purpose being 
to improve the power of statistics, our analyses used the 
composite indicator – metabolic health rather than single 
metabolic biomarker in the multivariable-adjusted models. 
Besides age, gender and follow-up time, other factors with 
significant univariate effect on diabetes risk were included 
into the final model. To avoid bias, we did not examine the 
association between diabetes risk and blood glucose levels, 
HbA
1c
 or HOMA-IR in the analyses since they were critical 
components of the definition of diabetes. Potential confound-
ers adjusted for in multivariable GEE models included age, 
gender, follow-up time, and time-varying BMI, white blood 
cell (WBC), insulin and metabolic health. Variables that were 
not significant or not confounders were excluded from the 
final model. The model including BMI did not include waist-
to-hip ratio (WHR)/WC at the same time due to its collinear-
ity with BMI. The exposure by follow-up time interaction 
term was also included into the model since it might suggest 
that the exposure might vary as time progresses. GEE model 
was also used to explore the predictors reflecting the transi-
tion from pre-diabetes to normal glucose level at the last visit.
The graph to present the cumulative incidence of dia-
betes over time was generated by a Cox regression model. 
To illustrate the risk for diabetes over time, we also used a 
restricted cubic spline GEE logistic regression analysis 26 to 
evaluate the risk of diabetes with follow-up months. Knots 
were placed at the 5th, 50th and 95th percentiles of the dis-
tribution of follow-up months.
Linear mixed-effects regression models with random 
intercept were used to estimate the association between 
repeated measures of markers such as plasma metabolic 
biomarker concentrations as the outcome (dependent vari-
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(independent variable). Separate models were used for each 
marker to examine the changes of each marker accompany-
ing transition. The models also controlled for covariates 
including follow-up months, time-varying BMI, time-varying 
metabolic health, age and gender. Interaction terms between 
diabetes and follow-up time were included to explore effect 
modification of the rate of transition to diabetes. The GEE 
model was used to analyze the effect of the transition from 
pre-diabetes to diabetes (independent variable) on the cat-
egorical variable, metabolic health (dependent variable). 
Potential confounders adjusted for in the multivariable GEE 
model included age, gender, follow-up time and BMI. The 
transition-to-diabetes by follow-up time interaction term was 
also included into the model.
Linear mixed-effects regression models were used to 
analyze the factors affecting the longitudinal change of fast-
ing plasma glucose or HbA
1c
 levels, respectively, after the 
diagnosis of pre-diabetes. Besides age, gender and follow-
up time, other factors with significant univariate effect on 
glucose level or HbA
1c
 levels were included into the final 
models, respectively.
Statistical analyses were carried out by using SAS version 
9.4 (SAS Institute, Cary, NC, USA). All statistical tests were 
based on 2-sided probability.
Results
The mean age of 285 DRS subjects with pre-diabetes at 
baseline was 50 years; 36% were male. During the average of 
27 months of follow-up (range: 3–129 months), 96 (33.7%) 
subjects transitioned from pre-diabetes to overt diabetes. The 
overall incidence density was 12.4/100 person-years, but 
14.7/100 person-years in metabolic unhealthy obese subjects 
at enrollment and 6.4/100 person-years in metabolic healthy 
normal weight subjects at enrollment. The overweight/obese 
and metabolically unhealthy subjects have shorter time to 
develop diabetes than the metabolic healthy normal weight 
subjects (35.2 versus 31.4 months). Participants had 2–18 
study visits (median 6 visits). The baseline BMI, WC, WHR 
and the levels of fasting glucose, HbA
1c
, CRP and DBP were 
significantly higher in subjects developing diabetes than those 
without. For other characteristics, no significant differences 
were observed between subjects developing diabetes and 
those without. Detailed characteristics by diabetes status 
during follow-up are shown in Table 1.
Table 2 presents the odds ratio (OR) of the transition 
from pre-diabetes to diabetes over time, and the overall 
associations between each marker and longitudinal overt 
diabetes development during 129-month follow-up after the 
pre-diabetes diagnosis. The risk of the transition from pre-
diabetes to diabetes was not significantly associated with 
follow-up time. However, WBC, insulin, HDLC, triglycer-
ides, metabolic health, BMI, WC, WHR and SBP were all 
significantly associated with the transition from pre-diabetes 
to diabetes in the crude analysis (all Ps<0.05), but these asso-
ciations were no longer significant for WBC, insulin, WHR 
and SBP after adjusting for age, gender, follow-up time and 
BMI or metabolic health. Other factors including physical 
activity and diet were not statistically associated with the 
risk of transition to diabetes. Since metabolic health included 
HDLC, triglycerides and BP by definition, it was not put into 
the multivariable-adjusted model together with its compo-
nents at the same time. In the final multivariable-adjusted 
GEE model (Table 3), only deteriorating metabolic health 
and higher BMI were significantly associated with the risk 
of transition to diabetes. The risk of diabetes increased 8% 
when BMI increased 1 kg/m2 (OR: 1.08; 95% CI: 1.05–1.11) 
excluding the effect of age, gender, metabolic health and 
follow-up period. Compared with the metabolically healthy, 
metabolically unhealthy DRS subjects increased their risk of 
transition to diabetes by 81% (OR: 1.81; 95% CI: 1.09–3.02) 
after adjusting for age, gender, BMI and follow-up time 
(Table 3). Interaction terms were not statistically significant 
in the final model. Table 4 shows the OR of the transition 
from pre-diabetes to normal glucose level at the last visit over 
time, and the significant influencing factors and longitudinal 
normal glucose transition during 129-month follow-up after 
the pre-diabetes diagnosis. The final model shows that insulin 
increment significantly decreased the possibility to transition 
from pre-diabetes to normal glucose level.
Figure 1 illustrates diabetes incidence increasing over 
time after adjusting for age, gender, metabolic health and 
time-varying BMI. Figure 2 visually depicts the shape of the 
relationship between follow-up time and diabetes risk after 
adjusting for potential confounding variables in a restricted 
cubic spline model. Follow-up months were inversely associ-
ated with the risk of diabetes, although the association was 
not significant (Ps for linear and nonlinear association >0.05).
Table 5 shows the changes of markers accompanying 
transition from pre-diabetes to diabetes during the 129-month 
follow-up after the diagnosis of pre-diabetes. Statistically 
significant positive crude associations were found between 
diabetes and both log-transformed insulin levels, BMI and 
WC, but the association for insulin concentration became 
non-significant after adjusting for follow-up time, age, gen-
der, metabolic health and BMI (P=0.07). At any follow-up 
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Transition from pre-diabetes to diabetes
Table 1 Cohort baseline characteristics according to the follow-up diabetes status: diabetes risk study (April, 2004–December, 2015)
Characteristics Overall Developed diabetes during follow-up
Yes (n=96) No (n=189) P-value
Categorical variables, n (%)
Gender
Men 102 (35.79) 28 (29.17) 74 (39.15) 0.10
Women 183 (64.21) 68 (70.83) 115 (60.85)
Employed
Yes 161 (56.49) 50 (52.08) 111 (58.73) 0.48
No 120 (42.11) 44 (45.83) 76 (40.21)
Ever cigarette smoking
Yes 39 (27.86) 8 (19.05) 31 (31.63) 0.13
No 101 (72.14) 34 (80.95) 67 (68.37)
Ever alcohol drinking
Yes 67 (58.26) 24 (61.54) 43 (56.58) 0.61
No 48 (41.74) 15 (38.46) 33 (43.42)
Education
Below high school 160 (56.14) 60 (62.50) 100 (52.91) 0.12
High school and above 125 (43.86) 36 (37.50) 89 (47.09)
Place of birth
Mexico 202 (71.13) 70 (72.92) 132 (70.21) 0.63
USA 82 (28.87) 26 (27.08) 56 (29.79)
Met minimum recommendations for physical activity of  
≥600 MET-minutes/week
Yes 41 (26.97) 8 (16) 33 (32.35) 0.03
No 111 (72.55) 42 (84) 69 (67.65)
Met recommendations of ≥5 servings of fruit and vegetables per day
Yes 40 (26.67) 14 (29.17) 26 (25.49) 0.64
No 110 (73.33) 34 (70.83) 76 (74.51)
Continuous variables, Mean (SE)
Age at enrollment (years) 50.24 (14.08) 52.06 (12.33) 49.31 (14.04) 0.10
MET-minutes/week of moderate and vigorous activity (n=153) 1487 (4638) 876 (2471) 1783 (5371) 0.26
Total portions of fruit and vegetables (n=150) 3.68 (3.10) 3.58 (2.62) 3.73 (3.32) 0.79
Anthropometrics
Body mass index (kg/m2) 31.53 (5.79) 33.73 (6.00) 30.41 (5.36) <.0001
Waist circumference (cm) 104.66 (13.02) 108.70 (12.54) 102.60 (12.79) 0.0001
Waist-to-hip ratio 0.93 (0.06) 0.94 (0.06) 0.93 (0.06) 0.03
Metabolic markers
Insulin (mg/dL)a 14.69 (1.87) 15.22 (1.55) 14.47 (2.01) 0.60
Fasting plasma glucose (mg/dL)a 106.81 (1.06) 109.17 (1.06) 105.63 (1.05) <.0001
HOMA-IRa 3.79 (1.89) 3.99 (1.56) 3.71 (2.03) 0.45
HbA1c (%) 4.68 (0.81) 4.86 (0.82) 4.59 (0.78) 0.01
HbA1c (mmol/mol) 28 (8.9) 30 (9.0) 27 (8.5) 0.01
Total cholesterol (mg/dL) 193.51 (38.10) 189.9 (36.34) 195.2 (38.93) 0.37
Triglycerides (mg/dL)a 141.23 (1.58) 144.82 (1.63) 139.57 (1.56) 0.61
HDLC (mg/dL) 48.21 (12.19) 46.95 (10.50) 48.81 (12.91) 0.33
LDLC (mg/dL) 116.07 (34.53) 114.1 (36.19) 117.0 (33.81) 0.58
Blood pressure
Systolic blood pressure (mmHg) 119.21 (15.13) 121.5 (15.62) 118.0 (14.78) 0.07
Diastolic blood pressure (mmHg) 73.99 (9.51) 75.89 (10.12) 73.03 (9.05) 0.02
Metabolically unhealthyb
Yes 59 (20.70) 21 (21.88) 38 (20.11) 0.73
No 226 (79.30) 75 (78.13) 151 (79.89)
Inflammatory markersc
High-sensitivity CRP (mg/L)a,c 3.71 (2.55) 4.65 (2.47) 3.33 (2.55) 0.03
WBC count (103/μL)c 6.42 (1.69) 6.59 (1.88) 6.33 (1.58) 0.25
Notes: aGeometric concentrations. bMetabolic health was defined as having less than 2 of the following metabolic abnormalities: systolic blood pressure ≥130 mmHg and/or 
diastolic blood pressure ≥85 mmHg or on antihypertensive medication; triglyceride ≥150 mg/dL; HDLC <40 mg/dL in men or <50 mg/dL in women. cThe number for CRP is 
58 in diabetes group and 120 in non-diabetes group; that for WBC is 86 and 172, respectively.
Abbreviations: CRP, C-reactive protein; HbA1c, glycated hemoglobin; HDLC, high-density lipoprotein-cholesterol; HOMA-IR, homeostasis model assessment insulin 
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Table 2 OR and 95% CIs reflecting the transition from impaired fasting glucose to diabetes, and the overall associations between each 
marker and longitudinal overt diabetes development during 129-month follow-up after the impaired fasting glucose diagnosisa
Effect Crude analysis Multivariable-adjusted analysisb
OR (95% CI) P-value OR (95% CI) P-value
Transition from impaired fasting glucose to overt diabetesc
Follow-up time (months) on diabetes risk 0.999 (0.99–1.01) 0.87 1.00 (0.99–1.01) 0.95
Inflammatory markers
CRP (mg/L)d
Main effect of the marker on diabetes risk 1.00 (0.99–1.02) 0.89 0.996 (0.98–1.01) 0.66
Follow-up time (months) on diabetes risk 1.01 (0.997–1.03) 0.13 1.01 (0.997–1.03) 0.11
WBC count (103/μL)
Main effect of the marker on diabetes risk 1.11 (1.01–1.22) 0.04 1.07 (0.96–1.20) 0.23
Follow-up time (months) on diabetes risk 0.999 (0.99–1.01) 0.86 1.00 (0.99–1.01) 0.96
Metabolic markers
Insulin (mg/dL)d
Main effect of the marker on diabetes risk 1.03 (1.01–1.05) 0.007 1.02 (0.99–1.05) 0.22
Follow-up time (months) on diabetes risk 1.00 (1.02–1.02) 0.78 1.00 (0.99–1.01) 0.99
HDLC (mg/dL)e
Main effect of the marker on diabetes risk 0.96 (0.92–0.998) 0.04 0.95 (0.91–0.99) 0.02
Follow-up time (months) on diabetes risk 0.96 (0.92–1.005) 0.08 0.96 (0.93–0.999) 0.046
Main effect×follow-up time on diabetes risk 1.001 (1.00–1.002) 0.04 1.001 (1.0002–1.002) 0.02
LDLC (mg/dL)e
Main effect of the marker on diabetes risk 1.01 (0.998–1.02) 0.09 1.01 (0.999–1.02) 0.09
Follow-up time (months) on diabetes risk 1.06 (1.02–1.10) 0.003 1.06 (1.01–1.10) 0.008
Main effect×follow-up time on diabetes risk 0.9995 (0.999–0.9999) 0.005 0.9996 (0.999–0.9999) 0.01
Total cholesterol (mg/dL)d
Main effect of the marker on diabetes risk 1.00 (0.99–1.01) 0.97 1.00 (0.99–1.01) 0.86
Follow-up time (months) on diabetes risk 1.01 (0.996–1.02) 0.18 1.01 (0.996–1.02) 0.20
Triglycerides (mg/dL)d
Main effect of the marker on diabetes risk 1.00 (1.00–1.01) 0.046 1.005 (1.001–1.01) 0.01
Follow-up time (months) on diabetes risk 1.01 (0.997–1.02) 0.14 1.01 (0.997–1.02) 0.14
Metabolic health statusd,f
Main effect of being metabolically unhealthy (yes versus 
no) on diabetes risk
2.03 (1.23–3.36) 0.006 1.81 (1.09–3.02) 0.02
Follow-up time (months) on diabetes risk 0.999 (0.99–1.01) 0.80 0.9997 (0.99–1.01) 0.96
Anthropometrics
BMI (kg/m2)d 
Main effect of the marker on diabetes risk 1.09 (1.06–1.11) <0.0001 1.09 (1.06–1.12) <0.0001
Follow-up time (months) on diabetes risk 1.00 (0.99–1.01) 0.89 1.00 (0.99–1.01) 0.95
Waist circumference (cm)
Main effect of the marker on diabetes risk 1.04 (1.03–1.05) <0.0001 1.03 (1.0001–1.06) 0.046
Follow-up time (months) on diabetes risk 1.00 (0.99–1.01) 0.94 1.00 (0.99–1.01) 0.92
WHR
Main effect of the marker on diabetes risk 1.04 (1.01–1.08) 0.009 1.05 (0.996–1.11) 0.08
Follow-up time (months) on diabetes risk 0.999 (0.99–1.01) 0.85 0.998 (0.86–1.16) 0.98
0.28 (SE: 0.13, P=0.04) kg/m2 and increased WC by 0.01 (SE: 
0.004, P=0.004) cm as compared with subjects who did not 
(the reference group), while controlling for other covariates. 
Transition to diabetes was also associated with deterioration 
in metabolic health by 9% (OR: 1.09; 95% CI: 1.003–1.18) 
compared with those who did not transition. No statistically 
significant associations were observed for other markers in 
the crude and adjusted model.
Table 6 presents the factors affecting the longitudinal 
change of fasting plasma glucose level after the pre-diabetes 
diagnosis. Besides age, gender and follow-up time, other factors 
with significant univariate effect on glucose level were included 
in the final model. Older age, higher BMI and concentrations 
of insulin, HbA
1c
 and triglycerides significantly contribute to 
the longitudinal increase in plasma fasting glucose concentra-
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Transition from pre-diabetes to diabetes
Crude analysis Multivariable-adjusted analysisb
OR (95% CI) P-value OR (95% CI) P-value
Blood pressure
Systolic blood pressure (mmHg)d
Main effect of the marker on diabetes risk 1.01 (1.003–1.02) 0.01 1.01 (0.999–1.02) 0.08
Follow-up time (months) on diabetes risk 0.999 (0.99–1.01) 0.88 1.001 (0.99–1.01) 0.93
Diastolic blood pressure (mmHg)d
Main effect of the marker on diabetes risk 1.01 (0.99–1.03) 0.23 1.01 (0.99–1.03) 0.24
Follow-up time (months) on diabetes risk 0.999 (0.989–1.01) 0.89 1.00 (0.99–1.01) 0.96
Met minimum recommendations for physical activity  
of ≥600 MET-minutes/week
Main effect of physical activity on diabetes risk 1.25 (0.61–2.56) 0.55 1.36 (0.63–2.95) 0.43
Follow-up time (months) on diabetes risk 1.008 (0.99–1.02) 0.23 1.007 (0.99–1.02) 0.30
Met recommendations of ≥5 servings of fruit and  
vegetables per day
Main effect of fruit and vegetables intake on diabetes 
risk
0.95 (0.37–2.46) 0.92 0.98 (0.38–2.52) 0.96
Follow-up time (months) on diabetes risk 1.008 (0.99–1.02) 0.25 1.007 (0.99–1.02) 0.29
Notes: aSeparate Generalized Estimating Equations models were used to test the transition from impaired fasting glucose to overt diabetes and the association between each 
marker (independent variable) and diabetes (dependent variable) over time. P<0.05 for the diabetes risk changes over time of the study for any marker. The estimate for the 
main effect of the marker represents the change in the OR of diabetes occurrence corresponding to a 1-unit increase in a marker at any follow-up time while holding all other 
predictors fixed. The estimate for the effect of metabolic health represents the change in the OR of diabetes occurrence corresponding to being metabolically unhealthy 
versus being metabolically healthy at any follow-up time, controlling for other predictors. The estimate for follow-up time on diabetes risk represents if there is a decline/
increase over time in the risk of diabetes when all other predictors are fixed. The estimate for the main effect×follow-up time interaction represents effect modification of 
the diabetes status change by a marker; the change in diabetes status in the marker over each month of follow-up time, holding other predictors constant. bAdjusted for 
age, gender and time-varying BMI. cAn average of 9 repeated measures at every 3 to 6 months for an average of 27 months (range: 3–129 months) since baseline. dP>0.05 for 
the interactions between time and markers and the model did not include the interaction term due to P>0.05. eFurther adjusted for the interaction term between time and 
markers. fMetabolic health was defined as having less than 2 of the following metabolic abnormalities: systolic blood pressure ≥130 mmHg and/or diastolic blood pressure 
≥85 mmHg or on antihypertensive medication; triglyceride ≥150 mg/dL; high-density lipoprotein cholesterol <40 mg/dL in men or <50 mg/dL in women.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDLC, high-density lipoprotein-cholesterol; LDLC, low-density lipoprotein-cholesterol; MET, metabolic 
equivalent; OR, odds ratio; WBC, white blood cell; WHR, waist-to-hip ratio.
Table 2 (Continued)
Table 3 Multivariable-adjusted OR and 95% CIs reflecting the 
transition from impaired fasting glucose to diabetes, and the association 
between factors and longitudinal overt diabetes development during 
129-month follow-up after the impaired fasting glucose diagnosisa
Factors Multivariable- 
adjusted analysisb
OR (95% CI) P-value
Follow-up time (months) 1.00 (0.99–1.01) 0.96
Age (years) 1.01 (0.996–1.02) 0.17
Gender (women versus men) 1.10 (0.73–1.67) 0.65
BMI (kg/m2) 1.08 (1.05–1.11) <0.0001
Metabolically unhealthy (yes versus no)c 1.81 (1.09–3.02) 0.02
Notes: aThe Generalized Estimating Equations model was used to test the transition 
from impaired fasting glucose to overt diabetes and the association between multiple 
factors and diabetes over time. The estimate for the effect of the factor (continuous 
variable) represents the change in the OR of diabetes occurrence corresponding to 
a 1-unit increase in a factor at any follow-up time while holding all other predictors 
fixed. bThe estimate for the effect of metabolic health represents the change in 
the OR of diabetes occurrence corresponding to being metabolically unhealthy 
compared with being metabolically healthy at any follow-up time, controlling for 
other predictors. The estimate for follow-up time on diabetes risk represents if 
there is a decline/increase over time in the risk of diabetes when all other predictors 
are fixed. The effect of the factor×follow-up time interaction terms was not 
significant in models. cAdjusted for age, gender, time-varying BMI, metabolic health. 
Waist-to-hip ratio was not adjusted for in this model due to its collinearity with 
BMI; homeostasis model assessment insulin resistance was not included in the model 
due to its calculation based on glucose and insulin. Metabolic health was defined as 
having less than 2 of the following metabolic abnormalities: systolic blood pressure 
≥130 mmHg and/or diastolic blood pressure ≥85 mmHg or on antihypertensive 
medication; triglyceride ≥150 mg/dL; high-density lipoprotein cholesterol <40 mg/dL 
in men or <50 mg/dL in women.
Abbreviations: BMI, body mass index; OR, odds ratio.
Table 4 Multivariable-adjusted OR and 95% CIs reflecting the 
transition from impaired fasting glucose to normal level, and 
the association between factors and longitudinal reverting to 
normal blood glucose level during 129-month follow-up after the 
impaired fasting glucose diagnosisa
Model* Multivariable- 
adjusted analysisb
OR (95% CI) P-value
Follow-up time (months) 1.04 (1.02–1.05) <0.0001
Age (years) 0.99 (0.96–1.01) 0.37
Gender (women versus men) 2.05 (0.97–4.33) 0.06
Insulin (mg/dL) 0.49 (0.31–0.78) 0.003
Notes: aEighty-two subjects were reverting to normal level at the last visit from 
impaired fasting glucose since enrollment. The Generalized Estimating Equations 
model was used to test the transition from impaired fasting glucose to overt diabetes 
and the association between multiple factors and diabetes over time. The estimate 
for the effect of the factor (continuous variable) represents the change in the OR of 
diabetes occurrence corresponding to a 1-unit increase in a factor at any follow-up 
time while holding all other predictors fixed. The estimate for the effect of metabolic 
health represents the change in the OR of diabetes occurrence corresponding to 
being metabolically unhealthy compared with being metabolically healthy at any 
follow-up time, controlling for other predictors. The estimate for follow-up time 
on diabetes risk represents if there is a decline/increase over time in the risk of 
diabetes when all other predictors are fixed. The effect of the factor×follow-up time 
interaction terms was not significant in models. bThe final multivariable-adjusted 
models included significant variables except for age, gender and follow-up period. 
*The final multivariable-adjusted models only included significant variables except 
for age, gender and follow-up period.
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Figure 1 The cumulative incidence of diabetes rate by follow-up time.






0 6 12 18 24 30 36 42 48 54 60 66 72 78




















84 90 96 102 108 114 120 126 132
Figure 2 Smoothed plot for ORs of the diabetes risk according to follow-up time.
Notes: The ORs were estimated by using the restricted cubic-spline Generalized Estimating Equations logistic models with knots placed at the 5th, 50th, and 95th percentiles 
of follow-up months. The linear regression was not significant (P=0.82), and the nonlinear regression was not significant (P=0.76). The model was adjusted for age, sex, 
metabolic health and time-varying body mass index.
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Transition from pre-diabetes to diabetes
Table 5 The changes of markers accompanying transition from impaired fasting glucose to overt type 2 diabetes during 129-month 
follow-up after the diagnosis of impaired fasting glucosea
Variables Crude analysis Multivariable-adjusted analysisb




Main effect of transition on CRP 0.11 (0.20) 0.57 –0.006 (0.19) 0.97
Follow-up time (months) effect on CRP 0.01 (0.002) <0.0001 0.01 (0.002) <0.0001
WBC count (103/μL)c,d
Main effect of transition on WBC 0.004 (0.02) 0.84 −0.001 (0.02) 0.97
Follow-up time (months) effect on WBC −0.0005 (0.0002) 0.04 −0.0005 (0.0003) 0.18
Metabolic markers
Insulin (mg/dL)c,d
Main effect of transition on insulin 0.18 (0.08) 0.02 0.13 (0.07) 0.09
Follow-up time (months) effect on insulin −0.003 (0.0008) <0.0001 −0.002 (0.0008) 0.003
HDLC (mg/dL)c,d
Main effect of transition on HDLC 0.02 (0.03) 0.57 0.02 (0.03) 0.60
Follow-up time (months) effect on HDLC −0.0009 (0.0003) 0.001 −0.001 (0.0003) <0.0001
LDLC (mg/dL)c,d
Main effect of transition on LDLC –0.01 (0.04) 0.75 −0.01 (0.04) 0.81
Follow-up time (months) effect on LDLC –0.001 (0.0004) 0.007 −0.001 (0.0004) 0.006
TC (mg/dL)c,d
Main effect of transition on TC 0.009 (0.02) 0.68 0.007 (0.02) 0.75
Follow-up time (months) effect on TC −0.0009 (0.0002) <0.0001 −0.001 (0.0002) <0.0001
TG (mg/dL)c,d
Main effect of transition on TG 0.02 (0.05) 0.68 0.02 (0.05) 0.74
Follow-up time (months) effect on TG −0.0004 (0.0005) 0.43 −0.0003 (0.0005) 0.49
Anthropometrics
BMI (kg/m2)d
Main effect of transition on BMI 0.34 (0.14) 0.02 0.28 (0.13) 0.04
Follow-up time (months) effect on BMI 0.002 (0.002) 0.26 0.01 (0.002) <0.0001
WC (cm)
Main effect of transition on WC 0.02 (0.005) 0.0001 0.01 (0.004) 0.004
Follow-up time (months) effect on WC 0.00,007 (0.00006) 0.17 −0.0001 (0.00005) 0.02
WHRd
Main effect of transition on WHR 0.007 (0.004) 0.07 0.008 (0.004) 0.054 
Follow-up time (months) effect on WHR 0.0003 (0.00,005) <0.0001 0.0002 (0.00,005) 0.003 
Blood pressure
SBP (mmHg)c,d
Main effect of transition on SBP −0.002 (0.009) 0.86 −0.003 (0.009) 0.78
Follow-up time (months) effect on SBP −0.00004 (0.0001) 0.71 −0.0003 (0.0001) 0.007
DBP (mmHg)c,d
Main effect of transition on DBP −0.01 (0.01) 0.35 −0.01 (0.01) 0.27
Follow-up time (months) effect on DBP −0.0002 (0.0001) 0.15 −0.0001 (0.0001) 0.40
Categorical variables Crude analysis Multivariable-adjusted analysise 
OR (95% CI) P-value OR (95% CI) P-value
Metabolically unhealthy (yes versus no)f
Main effect of transition on metabolically unhealthy 1.10 (1.02–1.20) 0.02 1.09 (1.003–1.18) 0.04
Follow-up time (months) effect on metabolically unhealthy 0.999 (0.998–0.9999) 0.03 0.999 (0.998–0.9999) 0.03
Notes: aSeparate linear mixed-effects models were used to test the associations between diabetes development (independent variable) and each marker (dependent variable) 
for an average of 9 repeated measures at every 3 to 6 months for an average of 27 months (range: 3–129 months) since baseline. The estimate for the main effect represents 
the difference in a marker with diabetes occurrence at any follow-up time, controlling for other predictors. The estimate for follow-up time represents the rate of a marker 
change; the difference in the marker per month of follow-up when all other predictors are fixed. For example, an estimate of 0.10 for the main effect represents an increase 
of 0.10 in a marker with diabetes occurrence at any follow-up time, controlling for other predictors. An estimate of 0.01 for follow-up time represents the increasing rate 
of 0.01 of a marker change; the increase of 0.01 in the marker per month of follow-up when all other predictors are fixed. bAdjusted for age, gender and time-varying BMI. 
Additionally adjusted for metabolic health for CRP, WBC, insulin, LDLC and TC. Adjusted for age, gender and metabolic health for BMI and WHR. cMarkers were natural 
log-transformed to achieve an approximately normal distribution. dP>0.05 for the interactions between time and markers and the model did not include the interaction term 
due to P>0.05. eAdjusted for age, gender and time-varying BMI. fThe Generalized Estimating Equations model was used to test the effect of transition from impaired fasting 
glucose to overt diabetes on metabolically unhealthy over time. The estimate for the effect of transition on metabolically unhealthy represents the change in the OR of 
diabetes occurrence corresponding to being metabolically unhealthy compared with being metabolically healthy at any follow-up time, controlling for other predictors. The 
estimate for follow-up time on metabolically unhealthy represents if there is a decline/increase over time in the risk for metabolically unhealthy when all other predictors are 
fixed. The effect of the factor×follow-up time interaction terms was not significant in models. 
Abbreviations: BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; HDLC, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein 
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older age, women (compared with men) and higher BMI and 
concentrations of insulin, fasting glucose, total cholesterol and 
DBP significantly contribute to the longitudinal increment of 
HbA
1c
 level after adjusting for follow-up time (Table 7).
Discussion
Our data show that the critical factors determining transition 
from pre-diabetes to diabetes in a high-risk Mexican- American 
cohort are poor metabolic health and increase in BMI. One-
third of our DRS subjects were observed to transition from pre-
diabetes to diabetes during an average period of 27 months (3 
months to nearly 11 years), with incidence density of 12.4/100 
person-years. Poor metabolic health was the major risk fac-
tor, with incidence density of 13.8/100 person-months and an 
increased risk of transition to diabetes of 81%. Increasing BMI 
over the same time period was also a factor in transition; by 
8% for each 1 kg/m2 increase in BMI. These data give strong 
indications that the opportunity to impact diabetes is great in 
those with pre-diabetes through improving overall metabolic 
health and controlling or reducing BMI.
These observations are entirely consistent with our previ-
ous study of the association of obesity and metabolic health 
with diabetes.25 In that study, highest prevalence of diabetes 
was in those obese with significant metabolic abnormalities 
and the second highest prevalence in those not obese but with 
significant metabolic abnormalities. Although obesity alone 
is important, metabolic health is more so.25 Not surprisingly, 
diabetes incidence increased over time among subjects with 
pre-diabetes. Older age and increased BMI, elevated insulin 
levels, HbA
1c
 and triglycerides significantly contribute to the 
longitudinal increase in plasma fasting glucose concentra-
tions after adjusting for follow-up time and gender. Similarly, 
older age, women (compared with men) and increased BMI, 
elevated insulin levels, fasting glucose, total cholesterol and 
DBP significantly contribute to the longitudinal increment of 
HbA
1c
 levels after adjusting for follow-up time.
Table 6 Estimates for multiple factors associated with the longitudinal change of fasting plasma glucose level after the impaired fasting 
glucose diagnosis among 285 Mexican-Americans, 2004–2015, in Cameron County Hispanic Cohort Studya
Multiple factors affecting fasting plasma glucose level (mg/dL) in one model Estimate (SE) P-value
Follow-up time (months) –0.0004 (0.0001) 0.001
Age (years) 0.001 (0.0003) <0.0001
Gender (women versus men) 0.0005 (0.009) 0.55
Body mass index (kg/m2) 0.003 (0.001) 0.0006
Glycated hemoglobin (%) 0.008 (0.003) 0.002
Insulin (mg/dL) 0.003 (0.0004) <0.0001
Triglycerides (mg/dL) 0.0002 (0.00,004) 0.0002
Notes: aLinear mixed-effects model was used to test the associations between fasting plasma glucose level (dependent variable) and factors affecting its change for an average 
of 9 repeated measures at every 3 to 6 months for an average of 27 months (range: 3–129 months) since baseline. Except age and gender, other factors with significant 
univariate effect on glucose level were included in the model. The estimate for the effect of each factor represents the difference in glucose level with 1-unit increase of 
each factor (continuous variables) at any follow-up time, controlling for other predictors. The estimate for the effect of gender represents the difference in glucose level 
with women versus men at any follow-up time, controlling for other predictors. The estimate for follow-up time represents the rate of glucose level change; the difference 
in the glucose level per month of follow-up when all other predictors are fixed. Glucose level was natural log-transformed to achieve an approximately normal distribution.
Table 7 Estimates for multiple factors associated with the longitudinal change of plasma HbA1c level after first observation of transition 
to impaired fasting glucose among 285 Mexican-Americans, 2004–2015, in Cameron County Hispanic Cohort Studya
Multiple factors affecting HbA1c (%) level in one model Estimate (SE) P-value
Follow-up time (months) 0.002 (0.0003) <0.0001
Age (years) 0.002 (0.0006) 0.0007
Gender (women versus men) 0.04 (0.01) 0.002
Body mass index (kg/m2) 0.003 (0.001) 0.02
Fasting plasma glucose (mg/dL) 0.003 (0.0005) <0.0001
Total cholesterol (mg/dL) –0.0007 (0.0001) <0.0001
Diastolic blood pressure (mmHg) 0.002 (0.0006) 0.0007
Notes: aLinear mixed-effects model was used to test the associations between plasma HbA1c level (dependent variable) and factors affecting its change for an average of 9
 
repeated measures at every 3 to 6 months for an average of 27 months (range: 3–129 months) since baseline. Except age and gender, other factors with significant univariate 
effect on HbA1c level were included in the model. The estimate for the effect of each factor represents the difference in HbA1c level with 1-unit increase of each factor 
(continuous variables) at any follow-up time, controlling for other predictors. The estimate for the effect of gender represents the difference in HbA1c level with women 
versus men at any follow-up time, controlling for other predictors. The estimate for follow-up time represents the rate of HbA1c level change; the difference in the HbA1c 
level per month of follow-up when all other predictors are fixed. HbA1c level was natural log-transformed to achieve an approximately normal distribution.
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Transition from pre-diabetes to diabetes
To our knowledge, our study is the first to examine proxi-
mal changes accompanying the transition from pre-diabetes 
to diabetes among a population of Mexican-Americans with 
extreme prevalence of diabetes (27.8%).12 Our findings show 
that deteriorating metabolic health and increased BMI are 
the most important modifiable risk factors in transition to 
diabetes. Although these principles are generally accepted, 
they are not widely applied in these high-risk individuals. 
Our data emphasize the concept that strategies to improve 
metabolic health and maintain or regain normal weight 
are key in individuals with pre-diabetes and essential to 
controlling the pandemic of diabetes. These concepts are 
supported by the literature. A Korean cohort of 406 subjects 
with pre-diabetes was followed-up every 3–6 months for up 
to 9 years.27 They report a transition rate from pre-diabetes 
to diabetes of 20%,27 which was lower than the proportion 
of the cases over total number of the subjects (33.7%), but 
higher than the rate of 12.5/100 person-years in our study. The 
reason for the differences may include ethnicity, population 
structure, lifestyles and environment, different definitions 
of pre-diabetes and more importantly, different measure-
ment methods. We used incidence density as the measure-
ment of the rate of transition to avoid the effect of different 
follow-up periods of time on the rate, or introducing other 
bias. That study reported that surrogate markers (30-minute 
post-load glucose and C-peptide concentrations) reflecting 
β-cell dysfunction were more closely associated with diabe-
tes transition than insulin resistance indices.27 However, all 
indices of β-cell dysfunction in that study were calculated 
by fasting glucose, which was included in the definition of 
diabetes and is, therefore, highly correlated with diabetes, 
introducing bias. In support of our findings, several studies 
have shown that the metabolic syndrome was a strong predic-
tor of incident diabetes.28–31 However, Asians develop diabetes 
at considerably lower BMI than Western populations,32 so it 
cannot be assumed that diabetes is a single disease entity but 
more likely it is a complex including type 1 diabetes and a 
range of maturity-onset diabetes.33 Racial/ethnic disparities 
in diabetes prevalence have become most pronounced, and 
Mexican-Americans had highest rate compared with other 
ethnic groups.34
Our findings extend observations in the literature. Ford35 
summarized the findings from 5 major studies that examined 
the risk of incident diabetes among subjects with the meta-
bolic syndrome as defined by National Cholesterol Education 
Program (NCEP) and the World Health Organization and 
reported that random-effects estimate of relative risk was 
3.08 (95% CI: 2.16–4.40, P for heterogeneity <0.001). One 
study by Stern et al28 showed that the metabolic syndrome 
as defined by the NCEP criteria can predict incident diabetes 
in the general population. The Strong Heart Study (SHS), 
which is a population-based longitudinal study, showed that 
the measures of baseline obesity help predict the transition 
to type 2 diabetes in non-diabetic American Indians in the 
future, compared with subjects with normal glucose toler-
ance at baseline.11
Being metabolically unhealthy is a pre-diabetes state and 
also a risk factor for the development of type 2 diabetes.36 
Impaired insulin secretion with insulin deficiency with or 
without insulin resistance is the pathophysiological basis 
for the development of type 2 diabetes.36 The underlying 
disturbances for the pathophysiology of abnormal triglycer-
ides in type 2 diabetes are hepatic overproduction and delay 
clearance of triglyceride-rich lipoproteins the synthesis and 
secretion of which is related to insulin resistance.37 Similarly, 
the potential mechanism to support that obesity is a predictor 
of the transition from pre-diabetes to diabetes may be related 
to the reduced insulin sensitivity in adipose tissues among 
individuals with impaired fasting glycemia.38 Hyperglyce-
mia in the fasting state seems primarily to be caused by an 
inherent insulin secretory dysfunction followed by a decline 
in hepatic insulin sensitivity.39 Although not statistically 
significant, our findings also show that baseline HOMA-IR 
was higher in DRS subjects transitioned from pre-diabetes 
to diabetes than those without (3.99 versus 3.71) (Table 1), 
while triglycerides were statistically higher in DRS subjects 
transitioned from pre-diabetes to diabetes compared with 
those without the transition (multivariable-adjusted OR: 
1.005; P=0.01) (Table 2). Besides, the etiology involved 
in the transition from pre-diabetes to diabetes includes 
environmental factors, physical inactivity, diet, smoking 
and genetic factors.38 Our study also found that more DRS 
subjects who did not transition from pre-diabetes to diabetes 
met minimum recommendations for moderate and vigorous 
physical activity of ≥600 MET-minutes/week compared 
with their counterparts at enrollment (33% versus 16%; 
P=0.03) (Table 1). The lack of association was likely because 
these factors are not significant determinants of developing 
diabetes from pre-diabetes. Alcohol and smoking are not 
generally identified as risk factors for diabetes and our study 
was no exception. The question of diet is more complex, but 
we utilize a standardized method of diet measurement and 
none of its components nor the instrument as a whole was 
associated with developing diabetes. Overall, the transition 
from pre-diabetes states to type 2 diabetes is characterized 
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on glucose metabolism: reduced hepatic insulin sensitivity, 
stationary β-cell dysfunction and/or chronic low β-cell mass, 
altered glucagon-like peptide-1 secretion and inappropriately 
elevated glucagon secretion.38
There are some limitations in our research. Some mea-
surements, such as physical activity, were self-reported, 
which may affect its precision as a predictor. We could not 
completely rule out the possibility of residual confounding 
due to unmeasured or inadequately measured covariates.
This study had several strengths. First, this well-
characterized cohort is derived from a general population-
based randomly selected Mexican-American cohort, thus 
avoiding bias inherent in studies drawing from clinic 
populations or other non-randomly selected populations 
with established disease or mixed ethnicity. Second, the 
high-intensity, longitudinal study design gives strong power 
to explore the predictors related to the transition from pre-
diabetes to diabetes, determine proximal changes accompa-
nying the transition and finally to define a high-risk group 
for diabetes prevention. Third, the long-term follow-up 
data are very precious as every 3 to 6 months’ follow-up 
is time, cost and personnel consuming. Dynamic measures 
of glucose regulation also enhanced the prognostic value 
for progression to diabetes. Fourth, the transition rate 
from pre-diabetes to diabetes in our study was measured 
by incidence density or person-time incidence rate. This 
measure excludes the effect of how many years each person 
contributed to the study when they developed diabetes and 
much more accurate than prevalence. To our knowledge, 
this is the first study to use incidence density to calculate 
the transition rate from pre-diabetes to diabetes. Finally, 
we used fasting plasma glucose to diagnose pre-diabetes 
in our population-based study due to practicability, cost 
and reproducibility compared with other tests. Thus, our 
population-based study examined the transition from pre-
diabetes to diabetes in a practical way.
In conclusion, compared with metabolically healthy pre-
diabetes DRS subjects, metabolically unhealthy pre-diabetes 
DRS subjects had increased risk of transition to diabetes. 
Pre-diabetes DRS subjects with higher BMI were also sig-
nificantly more likely to convert to diabetes. Being metaboli-
cally unhealthy or having higher BMI level accompanied the 
transition. Being metabolically unhealthy and higher BMI 
are modifiable harmful factors amenable to modification and 
reduction of risk in Mexican-Americans. Efforts should be 
primarily focused on improving metabolic health and weight 
control intervention.
Highlights
•	 Deteriorating metabolic health and/or increasing 
body mass index (BMI) significantly raises the risk 
of  transitioning from pre-diabetes to diabetes among 
Mexican-Americans with pre-diabetes.
•	 Transition itself was accompanied by further increase in 
BMI and deterioration in metabolic health.
•	 These data underline the importance of improving meta-
bolic health and avoiding weight gain in pre-diabetes as 
simple but clear diabetes prevention targets and empha-
size the importance of lifestyle management.
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